{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:31:02Z","timestamp":1756996262688},"reference-count":0,"publisher":"Canadian Science Publishing","issue":"12","license":[{"start":{"date-parts":[[1984,12,1]],"date-time":"1984-12-01T00:00:00Z","timestamp":470707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.nrcresearchpress.com\/page\/about\/CorporateTextAndDataMining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Physiol. Pharmacol."],"published-print":{"date-parts":[[1984,12,1]]},"abstract":"<jats:p> Norepinephrine-stimulated prostacyclin synthesis was studied in rat aortic rings by measuring 6-keto-prostaglandin F<jats:sub>1\u03b1<\/jats:sub> (6-keto-PGF<jats:sub>1\u03b1<\/jats:sub>) by radioimmunoassay. Norepinephrine (10<jats:sup>\u22126<\/jats:sup>\u2002M) results in a 10- to 20-fold increase in 6-keto-PGF<jats:sub>1\u03b1<\/jats:sub> synthesis by rat aortic rings (54\u2002\u00b1\u200211 to 437\u2002\u00b1\u2002260\u2002pg\u2219mg wet weight<jats:sup>\u22121<\/jats:sup>\u221920\u2002min<jats:sup>\u22121<\/jats:sup>). The maximal stimulation of 6-keto-PGF<jats:sub>1\u03b1<\/jats:sub> synthesis was observed with a norepinephrine concentration of 10<jats:sup>\u22125<\/jats:sup>\u2002M at a mean effective concentration (EC<jats:sub>50<\/jats:sub>) of 9.5\u2002\u00b1\u20023.2\u2002\u00d7\u200210<jats:sup>\u22127<\/jats:sup>\u2002M which is similar to the contractile response (E<jats:sub>max<\/jats:sub>\u2002=\u200210<jats:sup>\u22125<\/jats:sup>\u2002M, EC<jats:sub>50<\/jats:sub>\u2002=\u20026.5\u2002\u00b1\u20021.8\u2002\u00d7\u200210<jats:sup>\u22127<\/jats:sup>\u2002M). Potassium chloride (30\u2002mM), although causing a similar maximal contractile response as 10<jats:sup>\u22126<\/jats:sup>\u2002M norepinephrine, did not increase 6-keto-PGF<jats:sub>1\u03b1<\/jats:sub> synthesis. Norepinephrine-stimulated 6-keto-PGF<jats:sub>1\u03b1<\/jats:sub> synthesis was dependent upon extracellular calcium. Norepinephrine stimulation in Ca<jats:sup>2+<\/jats:sup>-free medium did not lead to a significant increase in 6-keto-PGF<jats:sub>1\u03b1<\/jats:sub> synthesis. However, on the introduction of Ca<jats:sup>2+<\/jats:sup>, 6-keto-PGF<jats:sub>1\u03b1<\/jats:sub> synthesis was restored to its initial level. Phentolamine (10<jats:sup>\u22126<\/jats:sup>\u2002M) (an \u03b1-adrenergic antagonist) and trifluroperazine (2.5\u2002\u00d7\u200210<jats:sup>\u22124<\/jats:sup>\u2002M) (a calmodulin inhibitor) completely inhibited norepinephrine-stimulated 6-keto-PGF<jats:sub>1\u03b1<\/jats:sub> synthesis, whereas verapamil 3\u2002\u00d7\u200210<jats:sup>\u22126<\/jats:sup>\u2002M (a calcium channel blocking drug) only partially inhibited synthesis (control, 74\u2002\u00b1\u200212; norepinephrine, 437\u2002\u00b1\u2002260; norepinephrine + verapamil, 123\u2002\u00b1\u20028\u2002pg\u2219mg wet weight<jats:sup>\u22121<\/jats:sup>\u221920\u2002min<jats:sup>\u22121<\/jats:sup>). Norepinephrine-stimulated prostacyclin synthesis is probably \u03b1-receptor mediated and appears to depend upon the opening of receptor-operated Ca<jats:sup>2+<\/jats:sup> channels. The operation of potential-dependent Ca<jats:sup>2+<\/jats:sup> channels (by 30\u2002mM KCl) in contrast, although known to be associated with an increase of intracellular Ca<jats:sup>2+<\/jats:sup>, does not stimulate PG synthesis. <\/jats:p>","DOI":"10.1139\/y84-225","type":"journal-article","created":{"date-parts":[[2011,4,24]],"date-time":"2011-04-24T08:53:14Z","timestamp":1303635194000},"page":"1341-1347","source":"Crossref","is-referenced-by-count":33,"title":["Norepinephrine-stimulated vascular prostacyclin synthesis. Receptor-dependent calcium channels control prostaglandin synthesis"],"prefix":"10.1139","volume":"62","author":[{"given":"Duncan","family":"Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Pountney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fitchett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"155","container-title":["Canadian Journal of Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/pdf\/10.1139\/y84-225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T16:21:33Z","timestamp":1578241293000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/10.1139\/y84-225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,12,1]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1984,12,1]]}},"alternative-id":["10.1139\/y84-225"],"URL":"https:\/\/doi.org\/10.1139\/y84-225","relation":{},"ISSN":["0008-4212","1205-7541"],"issn-type":[{"value":"0008-4212","type":"print"},{"value":"1205-7541","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,12,1]]}}}